Joseph Stringer’s rating is based on several positive developments at Pliant Therapeutics. The company has provided a clear timeline for its key programs, notably the completion of enrollment for the ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Wireless intercom provider Pliant Technologies said it has expanded its sales network, adding manufacturer’s representative ...

Several scions of erstwhile royal families, including BJP minister Jyotiraditya Scindia, on Thursday slammed Rahul Gandhi for ...

Royal scions and BJP leaders have sharply criticized Rahul Gandhi for his recent comments on the role of princely states ...

Your selective amnesia about your own privilege is a disservice to those truly striving against adversity. Your dissonance ...

Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment ...

“The East India Company choked India by partnering with, bribing, and threatening our more pliant maharajas and nawabs,” read an Indian Express column by Opposition leader Rahul Gandhi. The mention of ...

In an opinion piece where he clarified his stance on business, Gandhi stated that India was subdued not by the business prowess of the East India Company but by its chokehold on the country.

周五，Stifel重申了对Pliant Therapeutics (NASDAQ:PLRX)股票的买入评级，目标价保持在32.00美元。该投资公司的前景仍然乐观，因为Pliant Therapeutics正在推进其Bexotegrast治疗特发性肺纤维化(IPF)的2/3期BEACON-IPF试验。IPF是一种以肺部瘢痕形成为特征的疾病，目前亟需有效的治疗方法。 预计该试验的2b期部分将在2025 ...